Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
https://seekingalpha.com/article/4722152-jazz-pharmaceuticals-zanidatamab-potential-growth-catalyst?source=feed_tag_editors_picks
Sep 19, 2024 - Jazz Pharma's diversified drug portfolio drives revenue growth. Zanidatamab shows promise with potential FDA approval in late 2024. See why I rate JAZZ as Hold.
0
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
https://www.zacks.com/stock/news/2332290/fda-accepts-axsm-s-nda-resubmission-for-migraine-drug-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2332290
Sep 05, 2024 - The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.
0
Why Is Jazz (JAZZ) Up 1.1% Since Last Earnings Report?
https://www.zacks.com/stock/news/2329735/why-is-jazz-jazz-up-1-1-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2329735
Aug 30, 2024 - Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
Avadel says court denies Jazz Pharma request on lumryz in narcolepsy (update)
https://seekingalpha.com/news/4144512-avadel-says-court-denies-jazz-pharma-request-on-lumryz-in-narcolepsy?source=feed_sector_healthcare
Aug 28, 2024 - Avadel Pharmaceuticals (AVDA) wins patent dispute against Jazz Pharmaceuticals (JAZZ) after court ruling.
0
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
https://www.zacks.com/stock/news/2326409/alkermes-alks-begins-narcolepsy-type-2-study-on-alks-2680?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2326409
Aug 23, 2024 - Alkermes' (ALKS) phase II Vibrance-2 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with narcolepsy type 2.
0
Jazz Pharma Epidyolex phase 3 trial fails in Japan
https://seekingalpha.com/news/4143105-jazz-pharma-epidyolex-phase-3-trial-fails-japan?source=feed_sector_healthcare
Aug 22, 2024 - Jazz Pharmaceuticals' Epidyolex (cannabidiol) phase 3 trial in Japan for seizures in pediatric patients failed. Read more here.
0
AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?
https://www.zacks.com/stock/news/2319883/amneal-pharmaceuticals-inc-amrx-soars-to-52-week-high-time-to-cash-out?cid=CS-ZC-FT-52_week_high-2319883
Aug 09, 2024 - Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
0
Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
https://www.zacks.com/stock/news/2316329/axsome-axsm-q2-loss-widens-y-y-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2316329
Aug 05, 2024 - Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.
0
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
https://www.zacks.com/stock/news/2313502/jazz-pharmaceuticals-jazz-beats-q2-earnings-and-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2313502
Jul 31, 2024 - Jazz (JAZZ) delivered earnings and revenue surprises of 13.25% and 2.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
0
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
https://www.zacks.com/stock/news/2294577/biotech-stock-roundup-alny-up-on-study-success-alim-on-merger-news-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2294577
Jun 27, 2024 - Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
0